Guggenheim analyst Chris Pasquale initiated coverage of Tandem Diabetes with a Buy rating and $76 price target. The analyst views the company as a "remarkable MedTech turnaround story." Management has successfully guided the company from a going concern risk at the start of 2018 to an over $4B market cap a year later, Pasquale tells investors in a research note. He sees the 19% pullback in the shares since March as creating an attractive entry point. The stock's current valuation is more than supported by Tandem's long-term growth outlook, and the upcoming Control-IQ launch representing an important near-term catalyst, says the analyst.